- Home
- DLY vs KURA Comparison
DLY vs KURA Comparison
Compare DLY & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- KURA
- Stock Information
- Founded
- DLY 2019
- KURA 2014
- Country
- DLY United States
- KURA United States
- Employees
- DLY N/A
- KURA N/A
- Industry
- DLY Investment Managers
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DLY Finance
- KURA Health Care
- Exchange
- DLY Nasdaq
- KURA Nasdaq
- Market Cap
- DLY 744.3M
- KURA 713.5M
- IPO Year
- DLY N/A
- KURA N/A
- Fundamental
- Price
- DLY $14.60
- KURA $9.88
- Analyst Decision
- DLY
- KURA Buy
- Analyst Count
- DLY 0
- KURA 14
- Target Price
- DLY N/A
- KURA $24.45
- AVG Volume (30 Days)
- DLY 215.9K
- KURA 1.7M
- Earning Date
- DLY 01-01-0001
- KURA 11-06-2025
- Dividend Yield
- DLY 8.93%
- KURA N/A
- EPS Growth
- DLY N/A
- KURA N/A
- EPS
- DLY N/A
- KURA N/A
- Revenue
- DLY N/A
- KURA $83,279,000.00
- Revenue This Year
- DLY N/A
- KURA $68.63
- Revenue Next Year
- DLY N/A
- KURA $141.59
- P/E Ratio
- DLY N/A
- KURA N/A
- Revenue Growth
- DLY N/A
- KURA N/A
- 52 Week Low
- DLY $13.26
- KURA $5.41
- 52 Week High
- DLY $15.95
- KURA $19.73
- Technical
- Relative Strength Index (RSI)
- DLY 18.02
- KURA 60.71
- Support Level
- DLY $15.11
- KURA $9.57
- Resistance Level
- DLY $15.26
- KURA $10.59
- Average True Range (ATR)
- DLY 0.13
- KURA 0.47
- MACD
- DLY -0.05
- KURA -0.02
- Stochastic Oscillator
- DLY 9.58
- KURA 64.34
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.